Fed up with Big Pharma | GenomeWeb

Fed up with Big Pharma

Premium

Michael Liebman is too modest to let it be put in print exactly how many job offers he was juggling this fall, but he will say that for scientists like him who have a clinical perspective on genomics, “it’s clear that the market opportunity is very, very great.” So plentiful are the options, in fact, that Liebman’s not limiting himself to just one new position.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.